The novel PARP inhibitor no. 123 induces DNA damage and activates cGAS-STING signaling to suppress cervical cancer

Compound No. 123, a novel PARP inhibitor derived from thiosemicarbazone dimers, was investigated for its antitumor activity against cervical cancer and its ability to modulate antitumor immunity via the cGAS-STING pathway. No. 123 potently inhibited PARP1 enzymatic activity (IC 50 = 73.18 ± 12.04 nM) and showed a computationally predicted binding mode within the PARP1 catalytic domain through multiple interactions with key residues including ASP-807, GLN-717, LYS-893, GLU-809, and ILE-879. In HeLa cells, No. 123 suppressed proliferation by inducing G2/M phase arrest and triggered mitochondrial-mediated apoptosis through ROS generation and modulation of the Bax/Bcl-2 ratio. Importantly, No. 123 induced DNA damage, as evidenced by increased γH2AX expression, leading to activation of the cGAS-STING pathway, as evidenced by increased phosphorylation of STING, TBK1, and IRF3. In a murine cervical cancer model, oral administration of No. 123 significantly suppressed tumor growth (inhibition rate: 92%) and modulated antitumor immunity, as evidenced by increased dendritic cell maturation and altered tumor-infiltrating immune cell composition. In vivo mechanistic studies confirmed that No. 123 induced DNA damage (increased γH2AX expression) and activated the cGAS-STING pathway, leading to upregulated expression of downstream inflammatory cytokines in tumor tissues. Notably, No. 123 exhibited a favorable safety profile with no apparent organ toxicity or alterations in serum ALT/AST levels. These findings establish No. 123 as a promising therapeutic candidate for cervical cancer that exerts antitumor effects through a dual mechanism involving direct cytotoxicity and cGAS-STING-mediated immune activation, independent of canonical HRD/BRCA mutations.

Authors

Institutions

Publication Details

Journal
Cell Biology and Toxicology
Published
2026-11-12
DOI
https://doi.org/10.1007/s10565-026-10315-8
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The novel PARP inhibitor no. 123 induces DNA damage and activates cGAS-STING signaling to suppress cervical cancer

Fengshu Fei, Xin Wang, Fangyu Jiao, Qianlong Fu et al.
Cell Biology and Toxicology
PARP inhibition in cancer therapy
article

The novel PARP inhibitor no. 123 induces DNA damage and activates cGAS-STING signaling to suppress cervical cancer

Fengshu Fei, Xin Wang, Fangyu Jiao, Qianlong Fu, Jianting Huang, Shiyu Ma, Chuanlong Guo, Nan Wang, Fangwei Zhang
article en

Abstract

Compound No. 123, a novel PARP inhibitor derived from thiosemicarbazone dimers, was investigated for its antitumor activity against cervical cancer and its ability to modulate antitumor immunity via the cGAS-STING pathway. No. 123 potently inhibited PARP1 enzymatic activity (IC 50 = 73.18 ± 12.04 nM) and showed a computationally predicted binding mode within the PARP1 catalytic domain through multiple interactions with key residues including ASP-807, GLN-717, LYS-893, GLU-809, and ILE-879. In HeLa cells, No. 123 suppressed proliferation by inducing G2/M phase arrest and triggered mitochondrial-mediated apoptosis through ROS generation and modulation of the Bax/Bcl-2 ratio. Importantly, No. 123 induced DNA damage, as evidenced by increased γH2AX expression, leading to activation of the cGAS-STING pathway, as evidenced by increased phosphorylation of STING, TBK1, and IRF3. In a murine cervical cancer model, oral administration of No. 123 significantly suppressed tumor growth (inhibition rate: 92%) and modulated antitumor immunity, as evidenced by increased dendritic cell maturation and altered tumor-infiltrating immune cell composition. In vivo mechanistic studies confirmed that No. 123 induced DNA damage (increased γH2AX expression) and activated the cGAS-STING pathway, leading to upregulated expression of downstream inflammatory cytokines in tumor tissues. Notably, No. 123 exhibited a favorable safety profile with no apparent organ toxicity or alterations in serum ALT/AST levels. These findings establish No. 123 as a promising therapeutic candidate for cervical cancer that exerts antitumor effects through a dual mechanism involving direct cytotoxicity and cGAS-STING-mediated immune activation, independent of canonical HRD/BRCA mutations.

Cell Biology and Toxicology
Qingdao University of Science and Technology (CN), Shandong University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Shandong Province
Good health and well-being
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon